IBI-80090
In November, 2012 IBI received FDA approval of its Orphan Drug Designation for IBI-80090 (mephalan for intraocular injection) for the treatment of retinoblastoma. IBI will be collaborating with Memorial Sloan Kettering Cancer Center on this project.